Citation Impact
Citing Papers
Differential Serum Levels of Eosinophilic Eotaxins in Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, and Autoimmune Hepatitis
2013 StandoutNobel
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
2018
Use of ursodeoxycholic acid in liver diseases
2001
Hepatocellular carcinoma
2003 Standout
Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
2006 Standout
Hepatic Disorders
1995
Hepatocellular carcinoma
2016 Standout
Hepatocellular carcinoma
2018 Standout
Locoregional Therapies for Hepatocellular Carcinoma: A Critical Review From the Surgeon’s Perspective
2002
Homozygous disruption of the murine MDR2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease
1993 Standout
Nonalcoholic Fatty Liver Disease
2002 Standout
Study of human isoursodeoxycholic acid metabolism
1997
Hepatocellular carcinoma
2021 Standout
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2019 Standout
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
2021 Standout
Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma
2010
A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma
2012
Vascular disorders of the liver # †
2008 Standout
Ursodeoxycholic Acid or Clofibrate in the Treatment of Non–Alcohol–Induced Steatohepatitis: A Pilot Study
1996
Thermal ablation of tumours: biological mechanisms and advances in therapy
2014 Standout
Are Patients with Child’s A Cirrhosis and Hepatocellular Carcinoma Appropriate Candidates for Liver Transplantation?
2011
Radiofrequency ablation versus microwave ablation for early stage hepatocellular carcinoma
2020
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
2003 Standout
Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆
1999 Standout
Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism
2016 Standout
Glutathione synthesis
2012 Standout
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
2012 Standout
Nonalcoholic fatty liver disease
2005 Standout
Tauro-β-muricholate preserves choleresis and prevents taurocholate-induced cholestasis in colchicine-treated rat liver
1992
Cystic Fibrosis Transmembrane Conductance Regulator Mediates the Cyclic Adenosine Monophosphate–Induced Fluid Secretion But Not the Inhibition of Resorption in Mouse Gallbladder Epithelium
1997 StandoutNobel
Scintigraphic Documentation of An Improvement in Hepatobiliary Excretory Function After Treatment With Ursodeoxycholic Acid in Patients With Cystic Fibrosis and Associated Liver Disease
1992
Radiofrequency Ablation versus Hepatic Resection for Small Hepatocellular Carcinomas: A Meta-Analysis of Randomized and Nonrandomized Controlled Trials
2014
Complications of radiofrequency coagulation of liver tumours
2002
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
AASLD guidelines for the treatment of hepatocellular carcinoma
2017 Standout
Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: a propensity score analysis
2018
Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma
2013
Primary Biliary Cirrhosis
2011 Standout
Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine.
2006 Standout
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Percutaneous Ablation for Hepatocellular Carcinoma: Comparison of Various Ablation Techniques and Surgery
2018
Ursodiol Prophylaxis against Hepatic Complications of Allogeneic Bone Marrow Transplantation
1998
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
2011 StandoutNobel
Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma
2011
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Chemical Chaperones Reduce ER Stress and Restore Glucose Homeostasis in a Mouse Model of Type 2 Diabetes
2006 StandoutScience
Works of Emanuela Bertolini being referenced
Effect of different doses of ursodeoxycholic acid in chronic liver disease
1989
Safety and efficacy of laparoscopic radiofrequency of hepatocellular carcinoma in patients with liver cirrhosis
2003
Radiofrequency interstitial thermal ablation of hepatocellular carcinoma in liver cirrhosis
2001
Comparison of Laparoscopic Microwave to Radiofrequency Ablation of Small Hepatocellular Carcinoma (≤3 cm)
2016
Surgical Resection Versus Laparoscopic Radiofrequency Ablation in Patients With Hepatocellular Carcinoma and Child-Pugh Class A Liver Cirrhosis
2009
Ursodeoxycholic acid for chronic liver diseases.
1988
External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort study
2017
Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: A dose-response study
1991
External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: a multicenter cohort study
2017
Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration
1991